Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
$AKTX
$ALLG
$APGN
$ARQQ
Biotechnology: Pharmaceutical Preparations
Health Care
Automotive Aftermarket
Consumer Discretionary
Gainers
- Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) gained 69% to $0.4664 after the company announced a 1-for-30 reverse stock split.
- Arqit Quantum Inc. (NASDAQ:ARQQ) shares climbed 34.7% to $7.53. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference later today.
- InMed Pharmaceuticals Inc. (NASDAQ:INM) gained 32.5% to $14.60 after the company on Friday announced a $6 million private placement priced at $8.68 per share.
- Ra Medical Systems, Inc. (NYSE:RMED) surged 28% to $0.1865 after the company announced a merger agreement with Catheter Precision. Catheter Precision will become a wholly owned subsidiary of Ra Medical.
- Vinco Ventures, Inc. (NASDAQ:BBIG) gained 25% to $1.2500.
- IHS Holding Limited (NYSE:IHS) jumped 19.2% to $7.47. IHS Holding, last month, said Q2 EPS results down year-over-year.
- Gogoro Inc. (NASDAQ:GGR) gained 19.1% to $5.16. Gogoro recently launched its battery-swapping system and Smart scooters in the Tel Aviv metropolitan area.
- Ribbon Communications Inc. (NASDAQ:RBBN) rose 19% to $3.8450.
- Allego N.V. (NYSE:ALLG) gained 18.3% to $5.23.
- Regulus Therapeutics Inc. (NASDAQ:RGLS) gained 16.8% to $1.94 after the company announced topline safety and PK data from its Phase 1 SAD clinical trial of RGLS8429. The study demonstrated that RGLS8429 has a favorable safety and PK profile.
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) surged 15.6% to $10.70. IDEAYA Biosciences disclosed interim Phase 2 clinical results for darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma.
- Carvana Co. (NYSE:CVNA) rose 13.7% to $41.64. Piper Sandler upgraded Carvana from Neutral to Overweight and lowered the price target from $98 to $73.
- POINT Biopharma Global Inc. (NASDAQ:PNT) gained 13.4% to $9.72 after the company published a poster at ESMO Congress 2022 highlighting updated safety and efficacy data from its Phase 3 SPLASH trial of PNT2002 in metastatic castration-resistant prostate cancer.
- Sigma Lithium Corporation (NASDAQ:SGML) jumped 12.8% to $28.16.
- Clovis Oncology, Inc. (NASDAQ:CLVS) rose 12.2% to $1.29 after the company said Rubraca (Rucaparib) as first-line maintenance treatment improves progression-free survival in women with advanced ovarian cancer across disease risk subgroups.
- Auddia Inc. (NASDAQ:AUUD) surged 12% to $1.40.
- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) gained 10.8% to $42.98 after jumping 26% on Friday.
- Genenta Science S.p.A. (NASDAQ:GNTA) gained 10.6% to $5.30.
- NIO Inc. (NYSE:NIO) surged 10.2% to $21.13 following positive analyst coverage from Deutsche Bank and BofA.
- NetScout Systems, Inc. (NASDAQ:NTCT) gained 9.7% to $33.70. The company, last month, posted upbeat quarterly earnings.
- Reborn Coffee, Inc. (NASDAQ:REBN) rose 9.4% to $2.5924. Dennis R Egidi recently reported a 9.5% stake in Reborn Coffee.
- Eve Holding, Inc. (NYSE:EVEX) gained 9.2% to $8.42. United recently announced a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
- Asana, Inc. (NYSE:ASAN) gained 9% to $26.87. Asana’s President, CEO and Director Dustin Moskovitz bought a total of 19,273,127 shares at an average price of $18.16.
- Quhuo Limited (NASDAQ:QH) shares rose 7.5% to $2.96 after the company on Friday said it has determined not to proceed with its proposed offering and sale of securities.
- Hyperfine, Inc. (NASDAQ:HYPR) rose 7.3% to $1.3090 after declining 6% on Friday. Hyperfine, last month, reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.
- Bristol-Myers Squibb Company (NYSE:BMY) rose 5.6% to $74.11. The FDA approved Bristol Myers Squibb Co's Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Atlantic Equities maintained Bristol-Myers Squibb with an Overweight and raised the price target from $83 to $87.
- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rose 4.3% to $1.35. The U.S. Food and Drug Administration has approved the company’s lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.
Losers
- Akari Therapeutics, Plc (NASDAQ:AKTX) shares dropped 25% to $0.7803 after the company announced a $12.75 million registered direct offering.
- Tuesday Morning Corporation (NASDAQ:TUEM) fell 22.7% to $0.2175 after the company secured commitment for strategic investment from group led by Retail Ecommerce Ventures, the owner of Pier 1 Imports and top consumer brands.
- Yoshiharu Global Co. (NASDAQ:YOSH) shares fell 22.5% to $3.2301. The company, on Friday, priced its IPO at $4 per share.
- DICE Therapeutics, Inc. (NASDAQ:DICE) fell 19.6% to $18.20. Stifel, last week, initiated coverage on the stock with a Buy rating and a $37 price target.
- CleanTech Acquisition Corp. (NASDAQ:CLAQ) dropped 17.7% to $5.02. CleanTech Acquisition and Nauticus Robotics completed business combination to trade under "KITT" effective September 13.
- Apexigen, Inc. (NASDAQ:APGN) declined 16.6% to $6.35 as the company announced the presentation of new data from a Phase 2 trial evaluating sotigalimab (sotiga) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.
- Leap Therapeutics, Inc. (NASDAQ:LPTX) dropped 15.3% to $1.43.
- Codere Online Luxembourg, S.A. (NASDAQ:CDRO) fell 15.6% to $2.70. Codere Online recently reported Q2 sales results.
- MOGU Inc. (NYSE:MOGU) fell 13.6% to $2.2475. Mogu’s board of directors, on Friday, authorized a new share repurchase program of up to $10 million of its shares.
- Nuwellis, Inc. (NASDAQ:NUWE) fell 12.1% to $0.7469.
- Entrada Therapeutics, Inc. (NASDAQ:TRDA) dropped 11.4% to $13.21. Entrada Therapeutics, last month, posted a Q2 loss of $0.74 per share.
- ShiftPixy, Inc. (NASDAQ:PIXY) fell 9.8% to $31.06 after gaining 11% on Friday.
- Azure Power Global Limited (NYSE:AZRE) dropped 9.3% to $5.32.
- Great Panther Mining Limited (NYSE:GPL) declined 9.2% to $0.2144.
- Immatics N.V. (NASDAQ:IMTX) fell 9% to $11.69.
- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) dropped 8.7% to $1.7250. Ayala Pharmaceuticals presented interim data from RINGSIDE pivotal Phase 2/3 trial of AL102 show confirmed partial response in desmoid tumors, at ESMO Congress.
- Burning Rock Biotech Limited (NASDAQ:BNR) declined 7.2% to $3.33.
- Digital Media Solutions, Inc. (NYSE:DMS) fell 6% to $2.0696. Digital Media Solutions shares climbed 72% on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash.
